EGFR and neoplasm: Unlike erlotinib treatment or dox withdrawal, which result in reduced phosphorylated EGFR (pEGFR) levels in tumor-bearing lungs, DT-treated tumors maintained pEGFR levels comparable to those of vehicle- and CRM197-treated tumors (Fig. 1B).